Partial agonist activity of celiprolol as assessed in conscious unrestrained dogs in comparison with those of pindolol and labetalol
- PMID: 2575385
Partial agonist activity of celiprolol as assessed in conscious unrestrained dogs in comparison with those of pindolol and labetalol
Abstract
The effects of celiprolol on the heart rate (HR) and the total peripheral resistance (TPR) were studied in chronically instrumented conscious dogs in comparison with those of pindolol, propranolol and labetalol. Intravenous injection of pindolol, celiprolol and labetalol increased the HR and decreased the TPR dose-dependently, whereas propranolol did not. The ratios of doses that elicited 12% changes in both parameters (HR12/TPR12) were 4.85 +/- 2.63, 0.61 +/- 0.03 and 0.42 +/- 0.11 for celiprolol, pindolol and labetalol, respectively, indicating the preferential reduction of TPR by celiprolol. Changes in HR and TPR produced by these three agents were antagonized by propranolol dose-dependently. However, inhibition by 3 mg/kg of propranolol was incomplete in the cases of labetalol-induced decrease in the TPR at the dose of TPR12 (51%) and celiprolol-induced increase in the HR at the dose of HR12 (89%). These results suggest that changes produced by celiprolol as well as pindolol and labetalol were mostly explainable by partial agonist activity via beta-adrenoceptors. However, the contribution of the alpha-blocking activity must also be taken into consideration in the case of the reduction of the TPR by labetalol. In addition, there is a possibility that celiprolol may increase HR via its direct action.
Similar articles
-
Cardiohemodynamic effects of bopindolol in normotensive conscious dogs. A comparative study with pindolol.Arzneimittelforschung. 1989 Apr;39(4):454-7. Arzneimittelforschung. 1989. PMID: 2568836
-
Celiprolol does not protect against ventricular tachycardia or sudden death in the conscious canine: a comparison with pindolol in assessing the role of intrinsic sympathomimetic activity.J Pharmacol Exp Ther. 1989 Nov;251(2):571-7. J Pharmacol Exp Ther. 1989. PMID: 2572693
-
Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol.J Cardiovasc Pharmacol. 1987;10 Suppl 11:S69-75. J Cardiovasc Pharmacol. 1987. PMID: 2454372 Clinical Trial.
-
[Intrinsic sympathomimetic action and its special features as demonstrated by the beta-1-receptor blocker celiprolol].Wien Klin Wochenschr Suppl. 1985;162:1-21. Wien Klin Wochenschr Suppl. 1985. PMID: 2861698 Review. German.
-
Celiprolol: a new beta adrenoceptor antagonist with novel ancillary properties.J Cardiovasc Pharmacol. 1986;8 Suppl 4:S29-32. J Cardiovasc Pharmacol. 1986. PMID: 2427849 Review.
Cited by
-
Celiprolol exerts microvascular dilatation by activation of beta 2-adrenoceptors.Naunyn Schmiedebergs Arch Pharmacol. 1992 Jul;346(1):27-31. doi: 10.1007/BF00167566. Naunyn Schmiedebergs Arch Pharmacol. 1992. PMID: 1357557
-
Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.Drugs. 1991 Jun;41(6):941-69. doi: 10.2165/00003495-199141060-00009. Drugs. 1991. PMID: 1715268 Review.
-
Hemodynamic effects of benazepril, an angiotensin-converting enzyme inhibitor, as studied in conscious normotensive dogs.Cardiovasc Drugs Ther. 1991 Jun;5(3):635-41. doi: 10.1007/BF03029732. Cardiovasc Drugs Ther. 1991. PMID: 1652276